New possibilities of pharmacotherapy for chronic obstructive pulmonary disease

• Main Authors: A. I. Sinopalnikov, A. G. Romanovskikh, Yu. G. Belotserkovskaya
• Format: Article
• Language: Russian
• Published: Remedium Group LLC 2018-10-01
• Series: Медицинский совет
• Subjects: chronic obstructive pulmonary disease; pharmacotherapy; vilenterol/umeclidinium; vilantherol / fluticasone furoate
• Online Access: https://www.med-sovet.pro/jour/article/view/2668

The use of bronchodilators (DB) remains up to the present day the leading therapeutic strategy for the treatment of chronic obstructive pulmonary disease (COPD), in which case administration of fixed-dose combinations of long-acting bronchodilators seem the most promising. At the same time, the issues of anti-inflammatory therapy of COPD are also actively discussed, first of which is feasibility for the wide use of fixed-dose combinations of inhaled glucocorticosteroids (IHGC) with long-acting β2-agonists (LABA). Recent years are characterized by the launch of a significant number of new BDs, anti-inflammatory drugs and their combinations to the pharmaceutical market. The article considers the role and place of new drugs in the treatment of COPD having a stable course.